Torrent Pharma collaborates with Boehringer Ingelheim India to co-market its anti-diabetic drug, its fixed dose combinations in India
Ahmedabad: Torrent Pharmaceuticals Ltd has entered into a strategic alliance with Boehringer Ingelheim India Private Limited to co-market Cospiaq (Empagliflozin), Cospiaq Met (Empagliflozin+ Metformin) and Xilingio (Empagliflozin+ Linagliptin) in India.
Empagliflozin is a novel sodium-glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus. Empagliflozin is also indicated to reduce the risk of cardiovascular death, in adults with type 2 diabetes mellitus and established cardiovascular disease. Further, empagliflozin is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure, in adults with heart failure.
As per International Diabetes Federation, India has the second largest diabetes patient base in the world with an estimated 74.2 million adults (20-79 years age group) as of 2021. This is expected to increase to almost 125 million patients by 2045. According to AWACS MAT October 2022 data, the Indian diabetes medications market is valued at INR 16,516 crore, growing at 8.6% CAGR over the last 4 years. The market for SGLT-2 Inhibitors is valued at 1,927 Crores and the SGLT-2 Inhibitors are growing faster than the diabetes market faster at 33% CAGR over the same time period.
Read also: Torrent Pharma to acquire Curatio healthcare for Rs 2,000 crores
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.